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HerpesvirusHeparan sulfate (HS) proteoglycans are commonly exploited by multiple viruses for initial attachment to host
cells. Herpes simplex virus-1 (HSV-1) is unique because it can use HS for both attachment and penetration,
provided speciﬁc binding sites for HSV-1 envelope glycoprotein gD are present. The interaction with gD is
mediated by speciﬁc HS moieties or 3-O sulfated HS (3-OS HS), which are generated by all but one of the seven
isoforms of 3-O sulfotransferases (3-OSTs). Here we demonstrate that several common experimental cell lines
express unique sets of 3-OST isoforms. While the isoforms 3-OST-3, -5 and -6 were most commonly expressed,
isoforms 3-OST-2 and -4 were undetectable in the cell lines examined. Since most cell lines expressed multiple
3-OST isoforms, we addressed the signiﬁcance of 3-OS HS in HSV-1 entry by down-regulating 2-O-sulfation, a
prerequisite for 3-OS HS formation, by knocking down 2-OST expression by RNA interference (RNAi). 2-OST
knockdown was veriﬁed by reverse-transcriptase PCR and Western blot analysis, while 3-OS HS knockdown
was veriﬁed by immunoﬂuorescence. Cells showed a signiﬁcant decrease in viral entry, suggesting an important
role for 3-OS HS. Implicating 3-OS HS further, cells knocked down for 2-OST expression also demonstrated
decreased cell–cell fusion when cocultivated with effector cells transfected with HSV-1 glycoproteins. Our
ﬁndings suggest that 3-OS HS may play an important role in HSV-1 entry into many different cell lines.
© 2009 Elsevier Inc. All rights reserved.Introduction
Herpes simplex virus type-1 (HSV-1), a member of the alpha-
herpesvirus family, causes a variety of diseases ranging from cold
sores or fever blisters on mucosal layers of the skin of the mouth and
face to much more severe, life threatening illnesses, such as keratitis,
encephalitis, and meningitis (Eisenstein et al., 2004; Whitley and
Roizman, 2001). The ability of HSV-1 to infect a wide array of cell
types leads to the diverse manifestations of HSV-1 infection. Heparan
sulfate (HS) is a glycosaminoglycan ubiquitously expressed on the
cell surface and extracellular matrix of almost all cell types as
heparan sulfate proteoglycans (HSPGs) (Lindahl et al., 1998; Rosen-
berg et al., 1997). HSPGs are composed of HS polysaccharide side
chains covalently linked to a protein core via a trisaccharide linker
region. HS has been shown to play a critical role during HSV-1
infection. During HSV-1 entry, HSV-1 viral particles ﬁrst attach to the
host cell surface by binding to HS using HSV-1 glycoproteins gB or gC
(Herold et al., 1991; Shieh et al., 1992; WuDunn and Spear, 1989).gy and Visual Sciences, College
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ll rights reserved.This enables HSV-1 glycoprotein gD to bind to one of its host cell
receptors, triggering fusion of the HSV-1 viral envelope with the host
cell plasma membrane, a process that also requires HSV-1 glycopro-
teins gB, gH, and gL. Fusion allows the HSV-1 viral capsid and
tegument proteins to be released into the host cell cytoplasm (Spear,
2004). A similar fusion mechanism is used when HSV-1 enters cells
through endocytosis and phagocytosis-like manners as well (Clement
et al., 2006; Nicola et al., 2003).
There are three separate classes of known HSV-1 gD entry receptors
(Spear, 2004). Nectin-1 and nectin-2 are members of the immunoglob-
ulin superfamily (Geraghtyet al., 1998; andWarner et al., 1998).Nectin-1
is the primary HSV-1 entry receptor in epithelial and neuronal cells
(Campadelli-Fiume et al., 2000; Haarr et al., 2001; Tiwari et al., 2008).
Herpes virus entry mediator (HVEM) belongs to the tumor necrosis
factor receptor family and is used for viral entry into human T
lymphocytes and trabecular meshwork cells (Montgomery et al., 1996;
Tiwari et al., 2005a). Finally, 3-O-sulfated heparan sulfate (3-OS HS),
which is a speciﬁcally modiﬁed form of HS generated by a family of
enzymes known as 3-O sulfotransferases (3-OSTs) (Shukla et al., 1999).
The 3-OST enzyme family consists of seven known isoforms (3-OST-1, -2,
-3A, -3B, -4, -5, -6), which can recognize speciﬁc monosaccharide
sequences arounduniquemodiﬁcation sites (Liu et al., 1999; Shukla et al.,
1999; Shworak et al., 1999). All 3-OST isoforms, except 3-OST-1, have
been shown to generate a formof 3-OSHS towhichHSV-1 gD canbind to
mediate viral entry (O'Donnell et al., 2006; Shukla et al., 1999; Tiwari et
390 C.D. O'Donnell et al. / Virology 397 (2010) 389–398al., 2005b; Xia et al., 2002; Xu et al., 2005). 3-OS HS is a unique HSV-1 gD
receptor due to the fact that it is a polysaccharide, containing speciﬁc
sulfated motifs that speciﬁcally mediate HSV-1 entry, while nectin-1,
nectin-2, and HVEM are all protein receptors.
HS polysaccharide chains are composed of repeating uronic acid
(D-glucuronic acid or L-iduronic acid) and D-glucosamine disaccharide
units (Lindahl et al., 1998; Rosenberg et al., 1997). During HS
biosynthesis, HS chains undergo extensive modiﬁcations, resulting
in the generation of a variety of structurally diverse HS chains (Fig. 1).
These modiﬁcations include N-deacetylation, N-sulfation, epimeriza-
tion, and sulfation at the 2-OH, 6-OH, and 3-OH positions (Lindahl et
al., 1998; Rosenberg et al., 1997). Interestingly, although both HSV-1Fig. 1.Heparan sulfate modiﬁcations. Heparan sulfate chains are initially synthesized as repea
modiﬁed by a series of enzymatic reactions, including N-deacetylation and N-sulfation of
glucuronic acid to iduronic acid, and O-sulfation at the 2-OH, 6-OH, and 3-OH positions. Fir
acetylated glucosamine and N-sulfo-glucosamine units, and ﬁnally 3-O-sulfation of glucosaand HSV-2 use HS as an attachment receptor during viral entry, HSV-1
can bind to distinct modiﬁcation sites on HS that HSV-2 is unable to,
which could explain some of the differences in cell tropism exhibited
by both viruses. For example, while N-sulfation and carboxyl groups
are required for both HSV-1 and HSV-2 infectivity, only HSV-1 is able
to bind the speciﬁc modiﬁcation sites generated by 2-O, 6-O, and 3-O
sulfations, which occur during 3-OS HS production (Herold et al.,
1996). During HS biosynthesis, 2-O sulfation is accomplished by the 2-
O-sulfotransferase (2-OST) enzyme, which is expressed as a highly
conserved single isoform (Shworak et al., 1999). The 3-O sulfation of
glucosamine residues, which generates HSV-1 gD binding sites on 3-
OS HS, takes place only after 2-O-sulfation has occurred (Fig. 1).ting disaccharide units ofN-acetylated glucosamine and glucuronic acid. HS can then be
N-acetylated glucosamine converting it to N-sulfo-glucosamine, C5 epimerization of
st is 2-O-sulfation of iduronic acid and glucuronic acid, followed by 6-O-sulfation of N-
mine residues. 2-O (red) and 3-O (green) sulfations are highlighted.
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nectin-1 and HVEM, as both have been shown to mediate HSV-2
infection as well (Taylor et al., 2007). This study focuses on the less
often studied, HSV-1 speciﬁc receptor, 3-OS HS. Our study demon-
strates cell type speciﬁc expression of 3-OST isoforms, the importance
of the 2-OST enzyme in the 3-OS HS biosynthetic pathway and
demonstrates the signiﬁcance of 3-OS HS during HSV-1 binding, entry,
and cell–cell fusion in a variety of cell types. Our study also identiﬁes
differences in the dependence on 3-OS HS as an HSV-1 entry receptor
by Vero, HeLa, and retinal pigment epithelial (RPE) cells.
Results
3-O sulfotransferase expression in various cell types
Though the majority of 3-OST isoforms generate HSV-1 speciﬁc gD
receptors, very limited information is available on their expression in
various experimental cell lines commonly used for studying HSV-1
infection. Previous studies looking at 3-OST tissue distribution
indicate 3-OSTs are expressed in a tissue speciﬁc manner. Isoforms
3-OST-2 and 3-OST-4 are predominantly expressed in the human
brain, 3-OST-5 is primarily expressed in human skeletal muscle tissue,
while the remaining 3-OST isoforms demonstrate a wider tissue
distribution (Lawrence et al., 2007; Shworak et al., 1999; Xia et al.,
2002; Yabe et al., 2005). To better understand the importance 3-OS HS
may play during HSV-1 entry, 3-OST expression was investigated in
various experimental cell lines using reverse-transcriptase PCR (RT-
PCR) to identify the range of cell lines expressing these enzymes. Most
3-OST isoforms were targeted, including 3-OST-2, 3-OST-3A, 3-OST-
3B, 3-OST-4, 3-OST-5, and 3-OST-6. The 3-OST-1 isoform was not
included since it fails to generate an HSV-1 gD receptor (Shukla et al.,
1999). CHO-K1 cells transfected with expression constructs for
individual isoforms served as positive controls.
Experimental cell lines analyzed in this study included mouse
neural P19N, HeLa, Vero, and retinal pigment epithelial (RPE) cells.
Each of these cell lines are commonly used for studying HSV-1
infection and provide excellent in vitromodels for studying viral entry
and replication. RT-PCR results showed each cell line expressed a
distinct set of 3-OST isoform mRNAs (Fig. 2). RPE cells expressed 3-
OST-3A, -3B, -5, and -6; HeLa cells 3-OST-3B, -5, and -6; and Vero cellsFig. 2. 3-OST isoform expression in various cell lines. RT-PCR detection of isoforms 3-OST-3A
P19N cells. CHO-K1 cells transfected with 3-OST isoforms (-3A, -3B, -5, -6) served as a posit
reverse transcriptase was used for RT-PCR. PCR products were separated by electrophoresis
604 bp (3-OST-3A), 442 bp (3-OST-3B), 777 bp (3-OST-5), and 570 bp (3-OST-6). β-Actin mRexpressed 3-OST-3A, -6, and possibly a very low expression level of 3-
OST-3B. Interestingly, expression of 3-OST-2 and 3-OST-4 was absent
in each cell line examined (data not shown). This result is not totally
unexpected since expression of both isoforms is highly restricted to
the human brain (Shworak et al., 1999). Among the various cell lines
examined, only P19N cells were found to not express any of the 3-OST
isoforms. While it is quite possible that P19N cells do not express any
of the known 3-OST isoforms, it is also possible RT-PCR failed to detect
any signals due to low expression of 3-OSTs in P19N cells.
Effect of 2-O sulfotransferase downregulation on receptor expression
Since the majority of cell lines examined expressed one or more 3-
OST isoforms, the signiﬁcance of 3-OS HS on HSV-1 infection was
examined by selectively knocking down the expression of enzymes
required for the generation of 3-OS HS using siRNA (Carthew and
Sontheimer, 2009). Since cells that expressed3-OSTsexpressedmultiple
isoforms, it makes it difﬁcult to use siRNA speciﬁc for 3-OSTs because
downregulation of one 3-OST isoform may not lead to a noticeable
decrease in 3-OS HS expression due to the expression of the remaining
3-OST isoforms still capable of generating3-OSHS. Also siRNA treatment
against each isoformmay prove to be too stressful for the cells. Instead,
the 2-OST enzyme was targeted instead. 2-O-sulfation is a prerequisite
for 3-O-sulfation of HS and the generation of 3-OS HS. Thus, targeting of
the individual 2-OST enzyme can prevent 3-O-sulfation and the
generation of 3-OS HS (Shukla et al., 1999). Downregulation of the
single 2-OST isoform prevents all 3-OST isoforms from generating 3-OS
HS without altering 3-OST expression (Sugahara and Kitagawa, 2002).
Cells were treated with a 2-OST speciﬁc siRNA construct
(Sigma) to downregulate 2-OST expression. Initially, 2-OST down-
regulation was veriﬁed after 2-OST siRNA treatment using RT-PCR.
For RT-PCR, Vero, HeLa, RPE, and CHO-K1 cells were tested. CHO-
K1 cells were transfected with nectin-1, HVEM, or the 3-OST-3B
isoform. CHO-K1 cells transfected with 3-OST-3B are able to
generate HSV-1 binding 3-OS HS and express it on the cell surface.
RT-PCR demonstrated that mRNA speciﬁc for 2-OST was down-
regulated in each cell line after treatment with 2-OST siRNA
compared to cells that were mock treated or transfected with a
negative control scrambled siRNA (Fig. 3). No downregulation was
seen in cells transfected with scrambled siRNA. CHO-K1 cells(a), 3-OST-3B (b), 3-OST-5 (c), and 3-OST-6 (d) was performed in Vero, RPE, HeLa, and
ive control. The cDNAs were produced from total RNA isolated from cells. Superscript II
on an agarose gel and stained with ethidium bromide. Expected PCR product sizes were
NA (bottom panels) was used as a control with an expected PCR product size of 285 bp.
Fig. 3. RT-PCR to verify reduced 2-OST gene expression. RT-PCR analysis of 2-OST expression was performed with HeLa, RPE, and Vero cells (a), and CHO-K1 cells expressing 3-OST-
3B, HVEM, or nectin-1 (b). Cells were mock treated (wt) or transfected with scrambled siRNA (+ negative siRNA) or 2-OST siRNA (+ siRNA). About 48 h after siRNA transfection,
total RNA was isolated from each cell line. Superscript II reverse transcriptase was used for RT-PCR. PCR ampliﬁcation of cDNA was done using speciﬁc 2-OST primers. Expected PCR
product sizes were 792 bp (2-OST) and 285 bp (β-actin) (bottom panels).
Fig. 4.Western blot analysis of 2-OST protein expression after siRNA down regulation.
2-OST protein expression wasmeasured in a sample of CHO-K1 cells treated with 2-OST
siRNA, scrambled siRNA, or mock treated cells (no siRNA). Protein expression was
measured 48 h after siRNA transfection. β-Actin protein expression was measured as a
loading control. Protein bands were quantiﬁed using NIH ImageJ v1.41.
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controls for subsequent HSV-1 entry experiments, also demon-
strated a downregulation of 2-OST expression (Fig. 3b).
Downregulation of 2-OST was also seen at the protein level using
Western blot analysis. Using CHO-K1 cells as a representative cell line,
treatment with 2-OST siRNA resulted in a signiﬁcant decrease in 2-
OST protein expression, further conﬁrming the speciﬁc downregula-
tion of 2-OST expression after 2-OST siRNA treatment (Fig. 4). HeLa,
Vero, and RPE cells also showed a signiﬁcant decrease in 2-OST
protein expression after siRNA treatment (data not shown). Protein
bands were quantiﬁed using NIH ImageJ v1.41 to better demonstrate
the downregulation of 2-OST expression observed after siRNA
treatment. 2-OST protein expression was quantiﬁed by calculating
the relative intensity of each 2-OST protein band in relation to the
corresponding band intensity of its β-actin expression.
Though the previous experiments showed 2-OST expression was
downregulated, it was still required to determine if 3-OS HS
expression was also reduced. Immunoﬂuorescence was performed
to verify that siRNA knockdown of 2-OST did, in fact, reduce 3-OS HS
surface expression. HeLa cells that were mock treated, transfected
with scrambled siRNA, or transfected with 2-OST speciﬁc siRNA were
incubated with the antibody HS4C3, which speciﬁcally targets 3-OS
HS (Ten Dam et al., 2006). Incubation with HS4C3 was done at 4 °C,
and after, cells were ﬁxed but not permeablized, before the FITC-
conjugated secondary antibody was added, to speciﬁcally label cell
surface 3-OS HS. FITC labeled cells were examined by confocal
microscopy to compare 3-OS HS expression. A signiﬁcant reduction in
cell surface 3-OS HS was observed in HeLa cells transfected with 2-
OST speciﬁc siRNA compared to those mock treated or transfected
with scrambled siRNA (Fig. 5). Signiﬁcantly reduced 3-OS HSexpression was also observed in Vero, RPE, and 3-OST-3B expressing
CHO-K1 cells (data not shown). Though some intracellular 3-OS HS
labelingwas seen, themajority of 3-OS HS staining occurred at the cell
membrane. Some minor 3-OS HS expression was seen in 2-OST siRNA
treated cells, which is most likely due to the fact that 2-OST expression
was not completely eliminated by siRNA knockdown, so it would be
expected to see someminor 3-OS HS expression. However, the results
suggest downregulation of 2-OST subsequently leads to a signiﬁcant
decrease in 3-OS HS expression.
Together, these results demonstrated that 2-OST siRNA transfec-
tion led to a signiﬁcant knockdown of 2-OST expression at both the
mRNA and protein levels, and this also led to a signiﬁcant decrease in
3-OS HS expression. These controls were necessary to verify the
efﬁcacy of 2-OST siRNA treatment on 3-OS HS downregulation before
investigating the effects of 3-OS HS on HSV-1 entry and fusion.
Fig. 5. Use of immunoﬂuorescence to conﬁrm reduced 3-OS HS expression. HeLa cells were incubated with the antibody HS4C3 for 1 h at 4°C. Cells were then ﬁxed for 20 min and
incubated with FITC conjugated anti-mouse IgG to label 3-OS HS surface expression. 3-OS HS surface expression was compared in HeLa cells that were mock treated (left panels) or
transfected with scrambled siRNA (middle panels) or 2-OST siRNA (right panels). Imaging was performed using confocal microscopy at a 60 oil objective.
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HeLa, Vero, and RPE cell lines all expressed distinct sets of 3-OST
isoforms, suggesting 3-OS HSmay play a crucial role as an HSV-1 entry
receptor in these cell lines. After verifying knockdown of 2-OST
expression and subsequent downregulation in 3-OS HS expression,
we next examined the effect of reduced 3-OS HS expression on HSV-1
entry. To demonstrate that any effects on viral entry due to 2-OST
knockdown were speciﬁc to 3-OS HS and not another gD receptor,
viral entry was also measured in CHO-K1 cells transfected with
nectin-1 or HVEM,without any 3-OS HS expression, which is naturally
absent in CHO-K1 cells. To also demonstrate speciﬁcity to 3-OS HS,
HSV-1 entry was measured in P19N cells which were shown to not
express any 3-OST isoforms; thus, siRNA treatment should have no
effect on entry in P19N cells. In addition, herpes simplex virus type-2
(HSV-2) entry was measured in HeLa, Vero, and 3-OST-3B expressing
CHO-K1 cells (Supplemental Fig. 1). HSV-2 cannot use 3-OS HS as a
receptor, so HSV-2 entry should not be affected by a downregulation
of 3-OS HS expression.
Previously described HSV-1 entry assays were used to compare
viral entry in 2-OST siRNA treated cells with those transfected with
scrambled siRNA or mock treated. Cells were infected with a
recombinant β-galactosidase expressing HSV-1 (KOS) gL86 reporter
virus (Shukla et al., 1999). A signiﬁcant decrease in HSV-1 entry was
observed in cells treated with 2-OST siRNA compared to those treated
with scrambled siRNA or mock treated (Fig. 6). RPE, HeLa, and Vero
cells all showed a similar decrease in viral entry of around 45–50%.
CHO-K1 cells expressing 3-OST-3B showed the most signiﬁcant
decrease in viral entry after 2-OST siRNA treatment, which was
expected since 3-OS HS is the only known HSV-1 gD receptor
expressed by these cells. The negative control was infected CHO-K1cells transfected with control pcDNA3.1 plasmid. These cells do not
express a gD receptor and are resistant to HSV-1 entry.
As expected, CHO-K1 cells expressing nectin-1 or HVEM that were
treated with 2-OST siRNA did not demonstrate a similar decrease in
viral entry; however, there did appear to be a minor decrease in CHO-
K1 nectin-1 expressing cells. Similar levels of HSV-2 entry were seen
in HeLa and Vero cells no matter if the cells were treated with siRNA
or not (Supplemental Fig. 1). This suggests siRNA treatment was not
having any bystander effects. CHO-K1 cells expressing 3-OST-3B also
showed no differences in viral entry after 2-OST siRNA treatment and
showed levels of entry similar to the negative control, which was
expected, because these cells do not express any HSV-2 gD receptors
and cannot mediate HSV-2 entry. P19N cells also showed no changes
in HSV-1 entry when treated with 2-OST siRNA, which was also
expected because they do not express any 3-OST isoforms (Supple-
mental Fig. 1). Together, these results highlight the speciﬁc effect of 3-
OS HS on HSV-1 entry, and the results suggest the reduction seen in
viral entry was speciﬁcally due to reduced 3-OS HS expression. This
supports the notion that decreased 2-OST expression can signiﬁcantly
decrease HSV-1 entry in cell lines that can use 3-OS HS as an entry
receptor and/or related functions.
Effect of 2-OST downregulation on HSV-1 binding
Since HS is involved in virus attachment, the decreased entry seen
in the previous ﬁgure could be in part due to reduced binding of HSV-
1 to the host cell surface. To determine if downregulation of 2-OST
expression did in fact have a signiﬁcant effect on HSV-1 binding, a
viral binding assay was performed, comparing HSV-1 binding to cells
in the presence and absence of 2-OST siRNA. According to the results,
there was some decrease in HSV-1 binding seen for each cell line in
Fig. 6. HSV-1 entry is dependent on 2-OST and 3-OS HS expression. HSV-1 entry was analyzed in HeLa, Vero, RPE, and CHO-K1 cells expressing 3-OST-3B, nectin-1, or HVEM. Cells
were mock treated (no siRNA) or transfected with scrambled siRNA or 2-OST siRNA. Cells were replated in a 96-well culture dishes and inoculated with β-galactosidase-expressing
recombinant HSV-1(KOS) gL86 for 6 h. The soluble substrate ONPG was added, and enzymatic activity was measured with a microplate reader at 410 nm.
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treated or treated with scrambled siRNA (Fig. 7). When compared
with corresponding scrambled siRNA controls, the decrease in
attachment ranged from about 8–16% in the 2-OST siRNA transfected
cells. The viral binding assay was performed at 4 °C, which allows for
viral attachment but not viral entry, using HSV-1 (K26GFP) virus,
which expresses the ﬂuorescent GFP protein. CHO-K1 cells expressing
nectin-1 also showed a decrease in HSV-1 binding, which could
explain why a minor decrease was seen in HSV-1 entry in these cells
after 2-OST siRNA treatment even though this cell line does not
express 3-OS HS. Though it appears decreased HSV-1 binding was
partially responsible for reduced HSV-1 entry, the results still suggest
3-OS HS is playing a critical role during the penetration step of HSV-1
entry as well.
The effect of 2-OST expression on HSV-1 mediated cell–cell fusion
After establishing the importance of 3-OS HS in HSV-1 entry, it was
next examined if 3-OS HS played a critical role in HSV-1 mediated
cell–cell fusion, which is one of the ways by which HSV-1 spreads
within a host. Interestingly, while expression of gD receptors, such as
3-OS HS, are required for cell–cell fusion, unmodiﬁed HS is notrequired, as it is during the attachment step of HSV-1 entry (Pertel et
al., 2001). Similar cells lines used for studying HSV-1 entry were also
used to determine the relative effects of 2-OST knockdown on cell–
cell fusion. A standard luciferase reporter gene based cell–cell fusion
assay was performed to quantify HSV-1 cell–cell fusion. Each cell line
was split into two populations: target and effector cells. Target cells
were transfected with a plasmid expressing the luciferase reporter
gene under the control of the T7 promoter. CHO-K1 target cells were
additionally transfected with nectin-1, HVEM, or 3-OST-3B. It was not
required to transfect the other cell lines with a gD receptor since they
naturally express them. Target cells were also mock treated or
transfected with scrambled siRNA or 2-OST speciﬁc siRNA. Effector
cells were transfected with plasmids expressing HSV-1 glycoproteins
gB, gD, gH and gL and a plasmid expressing T7 RNA polymerase.
According to the results, most cell lines showed a signiﬁcant
decrease in cell–cell fusion when target cells were treated with 2-OST
siRNA compared to those mock treated or treated with scrambled
siRNA (Fig. 8). HeLa, RPE, and CHO-K1 cells expressing 3-OST-3B all
showed a similar decrease in cell–cell fusion. HeLa and RPE cells,
which express other gD receptors, still showed about 55% decrease in
cell–cell fusion compared to cells treated with scrambled siRNA,
highlighting the importance of 3-OS HS during this process.
Fig. 7. 2-OST downregulation affects HSV-1 binding. HSV-1 binding to the cell surface
was measured in Vero, HeLa, RPE, and CHO-K1 cells expressing either 3-OST-3B or
nectin-1 that were mock treated (no siRNA) or transfected with either scrambled siRNA
or 2-OST siRNA. About 48 h after siRNA transfection, cells were infected with HSV-1
(K26GFP) (10 M.O.I.) for 1 h at 4 °C. Fluorescence readings were taken using a GENios
Pro ﬂuorescence reader.
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whichmay indicate, in the case of Vero cells, HSV-1 gD receptors other
than 3-OS HS play a primary role in HSV-1 cell–cell fusion. Since Vero
cells showed a similar decrease in HSV-1 entry compared to the other
cell lines tested, the results also suggest that 3-OS HS may have
additional functions during HSV-1 entry, at least in the case of Vero
cells.
P19N cells, which were shown not to express any 3-OST isoforms,
did not show a decrease in cell–cell fusion when treated with 2-OST
siRNA (Supplemental Fig. 2). In addition, effector cells transfected
with the HSV-2 glycoproteins necessary to induce cell–cell fusion (gB-
2, gD-2, gH-2, gL-2) also did not show a decrease in cell–cell fusion
when treated with 2-OST siRNA (Supplemental Fig. 2). CHO-K1 cells
expressing 3-OST-3B showed levels of fusion similar to the negativeFig. 8. Cell–cell fusion is differentially affected by 2-OST downregulation in various cell lines
were mock treated (wild type), treated with scrambled siRNA (+negative siRNA), or treate
cells were mixed together in a 1:1 ratio and luciferase activity was measured after 24 h.control because these cells do not permit HSV-2 mediated cell–cell
fusion. Together, these results reinforce the idea that it is speciﬁcally
the downregulation of 3-OS HS that is causing the decrease in cell–cell
fusion. Cells not expressing 3-OS HS or cells infected with a virus that
does not use 3-OS HS as a receptor showed no effect on entry or cell–
cell fusion when 3-OS HS was downregulated.
Discussion
HSV-1 entry and cell–cell fusion are complex processes requiring
participation frommultiple viral glycoproteins and cell receptors. This
study provides further insight into the functions of the lesser
understood gD receptor, 3-OS HS. For the ﬁrst time, we demonstrate
most experimental cell lines tested express mRNAs for multiple 3-
OSTs raising a strong possibility that their ﬁnal product, 3-OS HS, is
also commonly expressed. While tissue speciﬁc expression of 3-OSTs
has been shown in the past (Lawrence et al., 2007; Shworak et al.,
1999; Yabe et al., 2005), little information on cell type speciﬁc
expression of 3-OSTs is known. Our results not only demonstrate
these cell lines express mRNAs for 3-OSTs but also suggest an
interesting possibility that each cell line expresses a unique signature
set of 3-OSTs. This possibility may be crucial for understanding the
normal physiological functions of 3-OSTs. Further studies must be
done to understand why 3-OSTs demonstrate cell-type speciﬁc
combinations.
This study also demonstrates, for the ﬁrst time, the broader
signiﬁcance of 3-OS HS in HSV-1 entry by showing a signiﬁcant
decrease in viral entry after downregulation of 3-OS HS that was
speciﬁc for cells expressing 3-OSTs. Even cell lines such as HeLa, Vero,
and RPE, which express multiple HSV-1 gD receptors, all showed a
signiﬁcant decrease in HSV-1 entry when transfected with 2-OST
siRNA. This suggests that 3-OS HS can still play a role in entry even
when other gD receptors are present.
However, it was interesting that such a signiﬁcant reduction in
entry occurred in these cells (∼50%) considering they express other
gD receptors. It seems highly unlikely that 3-OS HS would constitute
50% of the HSV-1 gD receptors present on the cell surface especially
since the treatment of HeLa cells with anti-nectin-1 can completely. Target cells for Vero (a), HeLa (b), RPE (c), and CHO-K1 cells expressing 3-OST-3B (d)
d with 2-OST siRNA (+siRNA). About 48 h after siRNA transfection, target and effector
396 C.D. O'Donnell et al. / Virology 397 (2010) 389–398block HSV-1 entry (Cocchi et al., 1998). If 3-OS HS did compose 50% of
the gD receptors, then how come antibodies against nectin-1 and
HVEM can block entry by more than 50%? One answer may lie in the
use of assays. Our assay (down regulation by siRNA) is different than
antibody blocking, which does not affect protein expression. Antibody
blocking may only affect the entry process while reduction in protein
expression may affect entry and any post entry events combined. It is
possible that 3-OS HS is also important for additional yet unknown
entry events and/or early post entry events as well, which may be a
reason why we saw signiﬁcant decrease in the reporter β-galactosi-
dase activity, which in essence is dependent on immediate early
transcription from the viral genome (Montgomery et al., 1996). The
combined effect, however, must be speciﬁc to cell types and HSV-1
since P19N and HSV-2 did not show any such effects (Supplemental
Fig. 1). Another possible explanation could be that 3-OS HS actually
has a novel function as a co-receptor for nectin-1 and HVEM. Studies
have shown that heparan sulfate proteoglycans can function as co-
receptors for a variety of cell surface molecules (Mythreye and Blobe,
2009). Thus, it is possible that nectin-1 and/or HVEMwork in concert
with 3-OS HS for efﬁcient mediation of entry and downregulating
either co-receptor may have relatively profound, but mutually
independent, effects on entry. A recent study (Satoh et al., 2008)
suggested that CHO-K1 cells, which were used for initial identiﬁcation
of HVEM and nectin-1 (Montgomery et al., 1996, Spear, 2004), may
naturally express low levels of 3-OST-3. The only exception here is
P19N cells, it is possible that a functional analog of 3-OS HS can take
over its functions during entry.
It is also possible that interfering with 3-OS HS may perturb
cellular signaling mechanisms required for efﬁcient virus entry and/
or post entry events. HS functions in a variety of signaling pathways
that regulate processes such as actin cytoskeleton reorganization,
apoptosis, NF-κB activation, and the inﬂammatory response, all of
which are involved in HSV-1 infection (Campo et al., 2009; Carr and
Tomanek, 2006; Gregory et al., 2004; Lindahl et al., 1998; Nguyen and
Blaho, 2007; O'Donnell and Shukla, 2009). While signiﬁcant informa-
tion is known about the role of HS in intracellular signaling, little is
known about the speciﬁc contribution of 3-OS HS in these signaling
pathways. Newer information suggest that 3-OS HS functions during
Notch signaling (Kamimura et al., 2004), in a ligand dependent
manner, and additional pathways may also be regulated by 3-OS HS
(Kobayashi et al., 2007). 3-OS HS knockout mice showed postnatal
lethality and intrauterine growth retardation, suggesting 3-OS HS
functions in other signaling pathways (Kamimura et al., 2004). 3-OS
HS may also be involved in the proliferation of various cancer cells
(Miyamoto et al., 2003). So it is tempting to speculate that initial
interactions with nectin-1 and/or HVEM are needed to mobilize the
fusion machinery while a parallel, and possibly independent,
interaction of gD with 3-OS HS can in addition activate signaling
pathways required for efﬁcient viral entry. At this point, we also
cannot discount the possibility that 3-OS HS may serve as a co-
receptor for an unknown signaling receptor, which is required for the
activation of signaling pathways required for entry. The ability of HS
to act as co-receptor to bring it into contact with other signaling
receptors is another feature of HS (Mythreye and Blobe, 2009).
Further work may provide evidence of an unknown function of 3-OS
HS during intracellular cell signaling.
This still does not explain why CHO-K1 cells expressing 3-OST-3B
do not show complete inhibition of entry or cell–cell fusion when
treated with 2-OST siRNA considering 3-OS HS was the only gD
receptor expressed on these cells.Western blot analysis showed siRNA
treatment did not completely inhibit 2-OST expression in CHO-K1
cells, suggesting there is still some 3-OS HS expression, which is one
possible explanation as to why entry and cell–cell fusion were not
completely inhibited. CHO-K1 cells transfected with 3-OST-3B over-
express the enzyme and likely overexpress 3-OSHS, possiblymaking it
more difﬁcult to completely inhibit 3-OS HS expression in these cells.This study also sheds light on the potential beneﬁt of blocking 2-
OST expression for inhibiting HSV-1 infection.While it is known that a
2-O-sulfated glucosamine is a prerequisite for 3-O sulfation, the direct
impact of 2-O-sulfation on HSV-1 infection was previously unknown.
We demonstrate for the ﬁrst time that reduced 2-O-sulfation, due to
2-OST knockdown, can inhibit HSV-1 entry and cell–cell fusion in
various cell lines. This observation identiﬁes a target for inhibiting 3-
OS HS mediated HSV-1 infection. Further studies can help elucidate
whether blocking of 2-OST activity, or earlier steps in the HS
biosynthetic pathway, can lead to the development of more effective
microbicides. Based on this study and other previous works (Herold et
al., 1996, Shukla et al., 1999), it is quite possible targeting 2-OST may
inhibit HSV-1 attachment, penetration, and spread via cell–cell fusion.
Though each cell line expressing 3-OST isoforms showed de-
creased HSV-1 entry, the effect of 3-OS HS downregulation on cell–cell
fusion was not as deﬁned. Our study shows various cell lines are
differentially affected by downregulation of 2-OST and reduced 3-OS
HS expression during HSV-1 cell–cell fusion. Unlike the other cell
types studied that showed a signiﬁcant decrease in cell–cell when
treated with 2-OST siRNA, Vero cells treated with 2-OST siRNA
showed only a minor decrease in cell–cell fusion, appearing to be the
least dependent on 3-OS HS for cell–cell fusion. The controls used for
this study suggest this decrease in cell–cell fusion may be a direct
result of reduced 3-OS HS expression.
Further studies must be done to determine why Vero cells showed
no decrease in cell–cell fusion. If 3-OS HS does function in intracellular
signaling that are critical for viral entry, it is possible 3-OS HS also
functions in signaling pathways activated during cell–cell fusion.
While HeLa, RPE, and CHO-K1 cells may depend on 3-OS HS mediated
signaling for cell–cell fusion, Vero cells may not rely on 3-OS HS for
the induction of these pathway(s), possibly because Vero cells express
another receptor that can perform a similar function. The fact that
Vero cells expressed the least amount of 3-OST isoforms could be why
these cells do not rely on 3-OH HS as much for cell–cell fusion. Unlike
the other cells lines tested, Vero cells did not express 3-OST-5, and if it
does express 3-OST-3B, it was still signiﬁcantly less than the other cell
lines. 3-OSTs have the ability to generate their own unique 3-OS HS,
with its own speciﬁc set of functions. This difference in 3-OST
expression between Vero cells and the rest of the cell lines tested
could be contributing signiﬁcantly to the differences seen between
these cells during cell–cell fusion.
RPE cells expressed the widest range of 3-OST isoforms and,
therefore, likely express relatively high levels of 3-OS HS. This may
be a primary reason why 2-OST knockdown had such a strong effect
on entry and cell–cell fusion. Ocular HSV-1 infection is a worldwide
epidemic resulting in diseases such as stromal keratitis, epithelial
keratitis, conjunctivitis, acute retinal necrosis, and possibly blind-
ness (Liesegang, 2001; Uchio et al., 2000). Evidence of cell–cell
fusion is particularly signiﬁcant because HSV-1 infection of retinal
cells can spread towards the cornea and conjunctiva, inducing the
most common and dangerous manifestations of HSV-1 ocular
disease. Due to lack of a curative treatment for HSV-1, prevention
of HSV-1 ocular spread is of great signiﬁcance. This study helps
show the potential signiﬁcance of 3-OS HS in preventing HSV-1
entry and spread during ocular infection. This can be studied further
in animal models in vivo. Further in vivo studies will be required to
develop a more accurate understanding of the HSV-1 infectious
process and to assess the beneﬁt of blocking 2-OST or 3-OS HS in
animal models.
While it is not completely clear why the downregulation of 2-OST
and subsequent reduction in 3-OS HS has such a signiﬁcant impact
on HSV-1 entry and cell–cell fusion, this study has helped provide
the groundwork for some very intriguing, and possibly very crucial,
novel functions 3-OS HS and 2-OST may be playing during HSV-1
infection. Further studies, not only on the speciﬁc role of 3-OS HS in
HSV-1 infection but on the physiological role of 3-OS HS in general,
397C.D. O'Donnell et al. / Virology 397 (2010) 389–398will be critical for furthering our understanding of 3-OS HS during
HSV-1 infection.
Materials and methods
Cells, viruses, siRNA, and antibodies
Wild type Chinese hamster ovarian (CHO-K1) and Vero cells were
provided by P.G. Spear (Northwestern University). CHO-K1 cells were
grown in Ham's F-12 medium (Gibco/BRL, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (FBS) and streptomycin/
penicillin (P/S) (Gibco/BRL). Vero cells were grown in DMEM (Gibco/
BRL) supplementedwith 5% FBS andP/S. RPE cells providedby B.Y. Yue
(University of Illinois at Chicago) were grown in DMEM (Gibco/BRL)
supplemented with 10% FBS, 5% fetal calf serum (FCS), and P/S. HeLa
cells obtained from B.P. Prabhakar (University of Illinois at Chicago)
were grown in DMEM supplementedwith 10% FBS and P/S. P19N cells
(ATCC; CRL-1825) were cultured as previously described (Kavouras et
al., 2007). The β-galactosidase expressing recombinant HSV-1(KOS)
gL86 virus was provided by P.G. Spear (Northwestern University). The
siRNA against human 2-OST was obtained from Sigma (Product #
SASI_Hs01_00214049, SASI_Hs01_00214052). HS4C3 antibody, which
targets 3-OS HS, was obtained from Toin H. van Kuppevelt (Radboud
University, Nijmegen, Netherlands) (Ten Dam et al., 2006). Experi-
ments using HS4C3 antibodywere performed in a 0.5-MNaCl solution
to increase the speciﬁcity of antibody to 3-OS HS.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total mRNA was isolated from the various cell lines tested using a
Qiagen RNeasy kit (Qiagen Co., Valencia, CA). Superscript II reverse
transcriptase (Invitrogen) was used for RT, and the following 3-OST
isoform primers were used for PCR ampliﬁcation of cDNA: 5′-
CCGGAAGTTCTTGCTGATGC-3′ and 5′-CCGCGTGACGAAGTAACTGG-3′
(3-OST-3A); 5′-CCACTGGCTTCAGGCAAGGA-3′ and 5′-TGGA-
CAGCGTCTGCGTGTAG (3-OST-3B); 5′-AGGCGTGGCTGAGACAGAAG-3′
and 5′-CTGGCAGAGGTTCCGTGATG-3′ (3-OST-5); 5′-CTCATCGTTGGCGT-
GAAGAA-3′ and 5′-GGTGGCGTTGAAGTAGAAGT-3′ (3-OST-6). RT-PCR
analysis was performed as described elsewhere (Tiwari et al., 2006).
Expected PCR product sizes were 604 bp (3-OST-3A), 442 bp (3-OST-3B),
777 bp (3-OST-5), and 570 bp (3-OST-6).
A similar method was used to determine 2-OST gene knockdown
approximately 48 after 2-OST siRNA transfection. 2-OST primers used for
PCR ampliﬁcation of cDNAswere 5′-CCAAGTTGCAGCTGCTGGCGGTGGT-
3′ and 5′-CCCTGAAAAACCGGGGCAATGCTGCCTCCA-3′. For PCR ampliﬁ-
cation of β-actin, which was used as a control, the primers 5′-
TCATGAAGTGTGACGTTGACATCCGT-3 ′ and 5 ′-CTTAGAAG-
CATTTGCGGTGCACGATG-3′ were used. Expected PCR product sizes
were 792 bp (2-OST) and 285 bp (β-actin).
Western blot analysis
Cells mock treated, treated with scrambled siRNA, or treated with
2-OST siRNA were lysed with cell lysis buffer supplemented with
protease inhibitor approximately 48 h after siRNA transfection. Cell
lysate was centrifuged at 12,000 × g for 15 min at 4 °C. Proteins were
resolved on SDS-PAGE gels and transferred to nitrocellulose mem-
branes. After blocking at room temp for 2 h in Tris buffered saline
(TBS) with 3% bovine serum albumin (BSA), anti-2-OST antibody
(1:500) (Abgent, Catalog # AP7648a) was incubated overnight at 4 °C.
After multiple washings, horse radish peroxidase (HRP) conjugated
anti-rabbit IgG (Jackson Immuno-Research Laboratories) was added
for 1 h at room temperature. After another round of multiple
washings, immunoreactive bands were developed with Super Signal
West Femto Maximum Sensitivity substrate (Pierce Biotechnology)and imaged on KODAK Biomax MR ﬁlm. β-actin protein expression
was measured as a loading control.
Cell imaging
HeLa cells were mock treated, transfected with scrambled siRNA,
or transfected with 2-OST siRNA, and after 48 h, cells were replated in
35 mm glass bottom dishes (MatTek) and incubated with HS4C3, an
antibody speciﬁcally targeting 3-OS HS, for 1 h at 4 °C. During
replating, cells were disassociated from the cell surface using Cell
Disassociation Buffer Enzyme-Free Hank's based (Gibco). After cells
were replated into glass bottom dishes, the cells were incubated at 37
°C for about 3–4 h to allow the cells to adhere to bottom of the dishes
before the HS4C3 antibody was added. Cells were washed with
phosphate buffer saline (PBS), ﬁxed for 20 min but not permeablized,
and washed again with PBS. Next, FITC-conjugated anti-mouse IgG
(Sigma) was added to cells for 1 h. Cells were washed again and fresh
media was added. FITC labeling was observed at the 60 NA 1.40 oil
objective on a confocal microscope (Leica DMIRE2) equipped with a
camera (Leica TCSSP2). Images were captured using Leica Confocal
Software v. 261.
HSV-1 viral entry assays
Entry assays were performed as previously described (Shukla et
al., 1999). Brieﬂy, cell lines were mock treated, transfected with
scrambled siRNA or 2-OST speciﬁc siRNA using LipofectAMINE 2000
(Invitrogen). CHO-K1 cells were previously transfected with 1 μg of 3-
OST-3B, nectin-1, or HVEM also using LipofectAMINE 2000. After
approximately 48 h, cells were disassociated from the culture dishes
using Cell Disassociation Buffer Enzyme-Free Hank's based (Gibco)
and replated into 96-well culture dishes. After the cells were replated,
the cells were incubated at 37 °C for about 3–4 h to allow the cells to
adhere to bottom of the dishes before virus was added. After the cells
were adhered, cells were infected with HSV-1(KOS) gL86 in a twofold
serial dilution for 6 h at 37 °C. After 6 h, cells were washed with PBS
and the soluble substrate o-nitrophenyl-β-D-galactopyranoside
(ONPG) was added. Enzymatic activity was measured at 410 nm
using a micro-plate reader (Spectra Max 190, Molecular Devices,
Sunnydale, CA USA). Cells infected with the β-galactosidase expres-
sing recombinant HSV-2 (333) gJ-virus strain was used as a control. A
similar protocol was followed as described above.
Viral binding assay
A previously described virus binding assay was used (Scanlan et
al., 2005). Cells that were mock treated, transfected with scrambled
siRNA, or transfectedwith 2-OST speciﬁc siRNAwere replated into 96-
well dishes about 48 h after siRNA transfection using Cell Disassoci-
ation Buffer Enzyme-Free Hank's based (Gibco). After incubating the
cells at 37 °C for about 3–4 h to allow them to adhere to bottom the
96-well dishes, the cells were washed once with PBS before addition
of virus. Cells were infected with HSV-1 (K26GFP), diluted in 50 μl of
Opti-MEM (Gibco), at an M.O.I. of 10 for 1 h at 4 °C. Cells treated with
Opti-MEM alone served as a negative control. After, cells were gently
washed with PBS. Fluorescence readings were taken using a GENios
Pro ﬂuorescence reader.
Cell–cell fusion assays
Cell–cell fusion assays were performed as previously described
(Pertel et al., 2001). For each cell line, cells were split into two
populations. “Target” cells were cotransfected with the luciferase
reporter gene (0.5 μg) and either mock treated, transfected with
scrambled siRNA, or transfected with 2-OST siRNA. CHO-K1 cells were
additionally transfected with 1 μg of 3-OST-3B. “Effector” cells were
398 C.D. O'Donnell et al. / Virology 397 (2010) 389–398transfected with plasmids expressing HSV-1 glycoproteins required
for cell–cell fusion (gD, gB, gH, gL) (0.5 μg) and T7 RNA polymerase
(0.5 μg). After 48 h, target and effector cells were mixed together in a
1:1 ratio and replated into 24-well culture dishes. Luciferase activity
was measured 24 h later. As a negative control, target cells were
mixed with effector cells lacking HSV-1 gD. For a control, fusion was
also measured when effector cells were transfected with 0.5 μg of the
four glycoproteins necessary to mediate HSV-2 cell–cell fusion: gB-2,
gD-2, gH-2, and gL-2.
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